FRED HUTCHINSON CANCER CENTER
๐บ๐ธUnited States
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Phase 1
Completed
- Conditions
- Adult Acute Myeloid Leukemia in RemissionChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Myeloid Leukemia in RemissionChildhood Myelodysplastic SyndromeChildhood Renal Cell CarcinomaChronic Myelomonocytic LeukemiaClear Cell Renal Cell Carcinomade Novo Myelodysplastic SyndromeMetastatic Renal Cell CancerPreviously Treated Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 106
- Registration Number
- NCT00027820
- Locations
- ๐บ๐ธ
Stanford University Hospitals and Clinics, Stanford, California, United States
๐บ๐ธUniversity of Arizona Health Sciences Center, Tucson, Arizona, United States
๐บ๐ธEmory University/Winship Cancer Institute, Atlanta, Georgia, United States
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00003199
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center/Puget Sound Oncology Consortium, Seattle, Washington, United States
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase 1
Completed
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Refractory Anemia With Excess BlastsRelapsing Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)B-cell Adult Acute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaPreviously Treated Myelodysplastic SyndromesAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- Biological: therapeutic allogeneic lymphocytesBiological: aldesleukinProcedure: peripheral blood stem cell transplantationProcedure: allogeneic bone marrow transplantationOther: laboratory biomarker analysisGenetic: gene expression analysisOther: immunologic techniqueOther: flow cytometryGenetic: polymerase chain reactionGenetic: cytogenetic analysisOther: staining method
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00052520
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant
Phase 1
Terminated
- Conditions
- Blastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Myelodysplastic SyndromesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Recurrent Adult Acute Myeloid LeukemiaRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00052598
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
Phase 2
Completed
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaAdult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00045435
- Locations
- ๐บ๐ธ
OHSU Cancer Institute, Portland, Oregon, United States
๐บ๐ธFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00002792
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Phase 2
Completed
- Conditions
- Recurrent Adult Acute Lymphoblastic LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlastic PhaseChildhood Acute Lymphoblastic Leukemia in RemissionChildhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent DiseaseAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chronic Phase of Disease
- Interventions
- Drug: CyclosporineDrug: DasatinibDrug: Fludarabine PhosphateDrug: Imatinib MesylateDrug: Mycophenolate MofetilDrug: NilotinibProcedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationBiological: Therapeutic Allogeneic LymphocytesRadiation: Total-Body Irradiation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00036738
- Locations
- ๐บ๐ธ
VA Puget Sound Health Care System, Seattle, Washington, United States
๐บ๐ธFred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
๐บ๐ธPresbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00005802
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Phase 2
Completed
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaContiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00040846
- Locations
- ๐ฎ๐น
University of Torino, Torino, Italy
๐บ๐ธPresbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
๐บ๐ธHuntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Recurrent Childhood Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Childhood Acute Myeloid Leukemia in Remission
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003875
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath